Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Merck: Regulatory Update on Cladribine Tablets
Zebrafish myelination: a transparent model for remyelination?
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
Intas launches biosimilar version of Rituximab
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
A full genome search in multiple sclerosis.
The scales and tales of myelination: using zebrafish and mouse to study myelinating glia.
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
Pharmacokinetics of CAMPATH-1H in BMT patients.
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis.
Withdrawal of the marketing authorization in the European Union
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.

Pages